Evaluation of Exposure to World Anti-Doping Agency Prohibited Substances in Healthy Volunteers: A Proof of Concept Study

The primary objective of the study titled "Study of exposure to substances prohibited by the World Anti-Doping Agency in **healthy volunteers** (ESPAMA_3)" is to evaluate the effects of exposure to substances that are banned by the World Anti-Doping Agency. This investigation is crucial for understanding the physiological and potential adverse effects of these substances in individuals without underlying health conditions. The study aims to provide insights that could inform anti-doping regulations and enhance the safety and integrity of competitive sports. No secondary objectives are specified for this study.

The clinical trial involves **healthy volunteers** as the study population, specifically focusing on male participants. The age range of the participants is categorized under code "3," which typically corresponds to a specific adult age group, although the exact age range is not specified. The total number of participants is not provided, as the sponsor has not given this information. The trial population was selected to exclude vulnerable populations, ensuring a focus on individuals without significant health issues. Lifestyle considerations such as diet, physical activity, and habits are not detailed in the available data. The study does not include female subjects, and no specific inclusion or exclusion criteria are highlighted in the provided information.

The clinical trial is designed to evaluate the exposure to substances prohibited by the World Anti-Doping Agency in **healthy volunteers**. This study is a Phase 3 trial, which is expected to commence recruitment on January 15, 2025, and conclude by January 15, 2027. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the experimental group or the control group, with neither the participants nor the researchers aware of the group assignments, thus maintaining the integrity of the data collected.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants will be assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following successful inclusion, participants will undergo a series of follow-up visits at specified intervals to monitor their health status and any potential effects of the substances being studied. These visits are essential for collecting data on the primary and secondary endpoints of the trial. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to gather comprehensive data for analysis.

The expected length of participant involvement in the trial is approximately two years, aligning with the overall trial duration. However, certain conditions may lead to early termination from the study, such as adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. These conditions are in place to ensure the safety and well-being of the participants throughout the trial. The study is conducted in accordance with ethical guidelines and regulatory requirements, ensuring that all procedures are scientifically sound and ethically justified.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 15, 2025, with an estimated completion date of January 15, 2027. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The study will focus on evaluating the therapeutic impact of the investigational product, with efficacy outcomes being a primary focus of the trial's objectives. The trial will be conducted in accordance with established clinical protocols to ensure the reliability and validity of the efficacy data collected.